Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
Not Confirmed
Not Confirmed
07-09 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Industry Trade Show
Not Confirmed
07-09 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/bms-j-j-bayer-lead-25-000-pharma-layoffs-in-2024-amylyx-fibrogen-kronos-bio-hit-by-trial-failures-cash-crunch
07 Feb 2024
// FDA
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-7-2024-67267.pdf
04 Oct 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/10/04/2527639/0/en/Arbor-Biotechnologies-to-Participate-in-the-2022-Cell-Gene-Meeting-on-the-Mesa.html
24 Dec 2021
// PHARMABIZ
24 Dec 2021
// PHARMABIZ
24 Aug 2021
// BIOSPACE
https://www.biospace.com/article/releases/azurity-pharmaceuticals-to-acquire-and-merge-with-arbor-pharmaceuticals/?s=79
07 Oct 2020
// FDA
https://www.pharmacompass.com/pdf/news/enforcement-report-for-week-of-october-7-2020-1602054141.pdf
Details:
Partnering with leading engineered cell therapy developers is a key component of Arbor’s strategy to broaden the potential of CRISPR discovery engine beyond the wholly-owned in vivo genetic medicine approaches for the benefit of even more patients.
Lead Product(s): Ex-vivo Engineered Cell Therapy
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Cell and Gene therapy
Sponsor: EdiGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 08, 2022
Lead Product(s) : Ex-vivo Engineered Cell Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : EdiGene
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Partnering with leading engineered cell therapy developers is a key component of Arbor’s strategy to broaden the potential of CRISPR discovery engine beyond the wholly-owned in vivo genetic medicine approaches for the benefit of even more patients.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 08, 2022
Details:
The combined company, operating as Azurity, will have a portfolio of products serving the unmet needs of patients in the cardiovascular, central nervous system, endocrinological, gastrointestinal, and institutional markets with many products like Epaned.
Lead Product(s): Enalapril Maleate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Epaned
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Azurity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 24, 2021
Lead Product(s) : Enalapril Maleate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Azurity
Deal Size : Undisclosed
Deal Type : Acquisition
Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals
Details : The combined company, operating as Azurity, will have a portfolio of products serving the unmet needs of patients in the cardiovascular, central nervous system, endocrinological, gastrointestinal, and institutional markets with many products like Epaned.
Brand Name : Epaned
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 24, 2021
Details:
The Phase 3 data being presented support Arbor’s New Drug Application (NDA) for AR19, which also includes data demonstrating that AR19 resists manipulation for nonmedical misuse and abuse by non-oral routes of administration.
Lead Product(s): Amphetamine
Therapeutic Area: Psychiatry/Psychology Brand Name: AR19
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Phase 3 data being presented support Arbor’s New Drug Application (NDA) for AR19, which also includes data demonstrating that AR19 resists manipulation for nonmedical misuse and abuse by non-oral routes of administration.
Brand Name : AR19
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 10, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?